Survey: ICER Assessments Impact Payer Decision-Making
Formulary Watch, Daniel Faraci and Kimberly Westrich
Payers see value in the cost-effectiveness analyses and policy reports conducted by the Institute for Clinical and Economic Review (ICER), according to a recent survey conducted by Xcenda and presented at the annual meeting of the Professional Society of Health and Economics and Outcomes Research (ISPOR) in May 2022. In fact, three quarters of the surveyed payers noted that ICER reports are at least somewhat impactful in their decision making process. “The assessments are most commonly used as a supporting source, but rarely the main source for coverage or formulary decision. In terms of formulary management, the results from ICER assessments are most often used in pricing negotiations, and to implement prior authorizations,” Daniel Faraci, research associate intern, market research, at Xcenda, said in an interview. Xcenda researchers conducted a double-blind, web-based survey of 50 of the company’s advisory group of payer experts, which represented health plans, integrated delivery networks, and pharmacy benefit managers.
For the full article, please visit Formulary Watch.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.